356 related articles for article (PubMed ID: 34383089)
21. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
22. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
23. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with
Ettala O; Malaspina S; Tuokkola T; Luoto P; Löyttyniemi E; Boström PJ; Kemppainen J
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):665-673. PubMed ID: 31879814
[TBL] [Abstract][Full Text] [Related]
24. A Comprehensive Assessment of
Abghari-Gerst M; Armstrong WR; Nguyen K; Calais J; Czernin J; Lin D; Jariwala N; Rodnick M; Hope TA; Hearn J; Montgomery JS; Alva A; Reichert ZR; Spratt DE; Johnson TD; Scott PJH; Piert M
J Nucl Med; 2022 Apr; 63(4):567-572. PubMed ID: 34326126
[TBL] [Abstract][Full Text] [Related]
25. A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
Alberts I; Bütikofer L; Rominger A; Afshar-Oromieh A
PLoS One; 2022; 17(7):e0270269. PubMed ID: 35853017
[TBL] [Abstract][Full Text] [Related]
26. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
[TBL] [Abstract][Full Text] [Related]
28. Comparison of
Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
[TBL] [Abstract][Full Text] [Related]
29. Matched-Pair Comparison of
Rauscher I; Krönke M; König M; Gafita A; Maurer T; Horn T; Schiller K; Weber W; Eiber M
J Nucl Med; 2020 Jan; 61(1):51-57. PubMed ID: 31253741
[No Abstract] [Full Text] [Related]
30.
De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P
Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
[TBL] [Abstract][Full Text] [Related]
31. Detection Efficacy of
Giesel FL; Knorr K; Spohn F; Will L; Maurer T; Flechsig P; Neels O; Schiller K; Amaral H; Weber WA; Haberkorn U; Schwaiger M; Kratochwil C; Choyke P; Kramer V; Kopka K; Eiber M
J Nucl Med; 2019 Mar; 60(3):362-368. PubMed ID: 30042163
[TBL] [Abstract][Full Text] [Related]
32.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
33. Head-to-Head Comparison of
Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
[No Abstract] [Full Text] [Related]
34. Interobserver variability, detection rate, and lesion patterns of
Miksch J; Bottke D; Krohn T; Thamm R; Bartkowiak D; Solbach C; Bolenz C; Beer M; Wiegel T; Beer AJ; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2339-2347. PubMed ID: 32157427
[TBL] [Abstract][Full Text] [Related]
35. Prospective comparison of
Zacho HD; Nielsen JB; Afshar-Oromieh A; Haberkorn U; deSouza N; De Paepe K; Dettmann K; Langkilde NC; Haarmark C; Fisker RV; Arp DT; Carl J; Jensen JB; Petersen LJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
[TBL] [Abstract][Full Text] [Related]
36. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
37. Prospective comparison of
Malaspina S; Anttinen M; Taimen P; Jambor I; Sandell M; Rinta-Kiikka I; Kajander S; Schildt J; Saukko E; Noponen T; Saunavaara J; Dean PB; Sequeiros RB; Aronen HJ; Kemppainen J; Seppänen M; Boström PJ; Ettala O
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2951-2959. PubMed ID: 33715033
[TBL] [Abstract][Full Text] [Related]
38. Comparison of
Regula N; Kostaras V; Johansson S; Trampal C; Lindström E; Lubberink M; Velikyan I; Sörensen J
Sci Rep; 2020 Mar; 10(1):4993. PubMed ID: 32193430
[TBL] [Abstract][Full Text] [Related]
39. Unspecific
Seifert R; Telli T; Opitz M; Barbato F; Berliner C; Nader M; Umutlu L; Stuschke M; Hadaschik B; Herrmann K; Fendler WP
J Nucl Med; 2023 May; 64(5):738-743. PubMed ID: 36460340
[No Abstract] [Full Text] [Related]
40. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]